Related Experiment Videos
Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients
Insights
Sudden cardiac death in hypertrophic cardiomyopathy (HCM) often affects young adults without prior limitations. Propranolol and other clinical factors do not reliably predict or prevent sudden death in HCM patients.
Area of Science:
- Cardiology
- Clinical Medicine
- Genetics
Background:
- Hypertrophic cardiomyopathy (HCM) is a primary cause of sudden cardiac death (SCD) in young individuals.
- Identifying at-risk patients for SCD in HCM remains a significant clinical challenge.
Purpose of the Study:
- To analyze the clinical and morphological characteristics of patients with HCM who experienced sudden cardiac death (SCD) or survived cardiac arrest.
- To determine predictors of SCD in hypertrophic cardiomyopathy.
Main Methods:
- Retrospective analysis of 78 patients with hypertrophic cardiomyopathy (HCM) who experienced sudden cardiac death (SCD) or survived cardiac arrest.
- Comparison of clinical, morphological, electrocardiographic (ECG), and hemodynamic variables between SCD patients and survivors.
Main Results:
- Most SCD events occurred in patients under 30 years old, often without functional limitations or with sedentary lifestyles.
- Propranolol did not offer absolute protection against SCD in 24% of patients.
- Ventricular septal thickness, abnormal ECGs, cardiac symptoms, and hemodynamic variables were not reliable predictors of SCD.
- Markedly increased septal thickness (≥20 mm) was common (77%) in those who died suddenly, but mean thickness did not significantly differ between SCD patients and survivors.
Conclusions:
- No single clinical or morphological variable reliably identifies patients with hypertrophic cardiomyopathy at high risk for sudden death.
- Current clinical assessment methods may be insufficient for predicting SCD in HCM.
- Further research is needed to identify reliable biomarkers or risk stratification tools for SCD in HCM.
Abstract:
The clinical profile of 78 patients with hypertrophic cardiomyopathy who died suddenly (or experienced cardiac arrest and survived) was analyzed. At the time of cardiac catastrophe, 71% of the patients were younger than 30 years of age, 54% were without functional limitation and 61% were performing sedentary or minimal physical activity. Nineteen of the 78 patients (24%) were taking propranolol in apparently adequate dosages, indicating that this drug does not provide absolute protection against sudden death. No clinical or morphologic variable was particularly reliable in identifying patients at risk for sudden death. Forty-eight of 62 patients (77%) who died suddenly had a markedly increased ventricular septal thickness of 20 mm or more; however, mean septal thickness was similar in patients who died suddenly (25.2 +/- 0.9 mm) and in age- and sex-matched control patients with hypertrophic cardiomyopathy who have survived (23.6 +/- 0.8 mm). An abnormal ECG was present as often in patients who died suddenly as in control patients who have survived, (51 or 53, 96%). In addition, no particular cardiac symptom or hemodynamic variable (such as the magnitude of left ventricular outflow tract obstruction under basal conditions or left ventricular end-diastolic pressure) was characteristic of the patients with hypertrophic cardiomyopathy who died suddenly.